Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight

被引:20
|
作者
Sharma, Jatin [1 ,2 ]
Bhardwaj, Vijay [1 ,2 ]
Purohit, Rituraj [1 ,2 ,3 ]
机构
[1] CSIR IHBT, Struct Bioinformat Lab, Palampur 176061, Himachal Prades, India
[2] CSIR IHBT, Biotechnol Div, Palampur 176061, Himachal Prades, India
[3] Acad Sci & Innovat Res AcSIR, CSIR IHBT Campus, Palampur 176061, Himachal Prades, India
来源
ACS OMEGA | 2019年 / 4卷 / 14期
关键词
PHOSPHATIDYLINOSITOL 3'-KINASE; CATALYTIC SUBUNIT; PROTEIN STABILITY; LIPID-BINDING; PI3K PATHWAY; 3-KINASE; ACTIVATION; P110-ALPHA; FLEXIBILITY; RAS;
D O I
10.1021/acsomega.9b01439
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
PI3K alpha is a heterodimer protein consisting of two subunits (p110 alpha and p85 alpha) which promotes various signaling pathways. Oncogenic mutation in the catalytic subunit p110 alpha of PI3K alpha at the 1047 position in the kinase domain substitutes the histidine with arginine. This mutation brings about conformational transitions in the protein complex. These transitions expose the membrane binding region of PI3K alpha, and then it independently binds to the cell membrane through its kinase domain without the involvement of the membrane-bound protein RAS. We observed notable changes between the protein complexes (p110 alpha-p85 alpha) of native and mutant structures at the atomic level using molecular dynamics simulations. Simulation results revealed formation of a less number of hydrogen bonds between the two subunits in the mutant protein complex which led the two subunits to move away from each other. This increase in distance between the subunits led to an expanded structure, thereby increasing the flexibility of the protein complex. Furthermore, a study of secondary structure elements and the electrostatic potential of the protein also gave a molecular insight into the change in interaction patterns of the protein with the plasma membrane. Our finding clearly indicates the role of mutation in oncogenesis and provides an insight into considering the structural aspects to handle this mutation.
引用
收藏
页码:15815 / 15823
页数:9
相关论文
共 50 条
  • [41] Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)
    Castanedo, Georgette M.
    Blaquiere, Nicole
    Beresini, Maureen
    Bravo, Brandon
    Brightbill, Hans
    Chen, Jacob
    Cui, Hai-Feng
    Eigenbrot, Charles
    Everett, Christine
    Feng, Jianwen
    Godemann, Robert
    Gogol, Emily
    Hymowitz, Sarah
    Johnson, Adam
    Kayagald, Nobuhiko
    Kohli, Pawan Bir
    Knueppel, Kathleen
    Kraemer, Joachim
    Krueger, Susan
    Loke, Pui
    McEwan, Paul
    Montalbetti, Christian
    Roberts, David A.
    Smith, Myron
    Steinbacher, Stefan
    Sujatha-Bhaskar, Swathi
    Takahashi, Ryan
    Wane, Xiaolu
    Wu, Lawren C.
    Zhang, Yamin
    Staben, Steven T.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (02) : 627 - 640
  • [42] INHIBITION OF PHOSPHOINOSITIDE-3-KINASE (PI3K)/AKT DEPENDENT SIGNALING INHIBITS [CA2+]I OSCILLATIONS IN HL-1 CARDIOMYOCYTES
    Graves, B.
    Wondergem, R.
    Simerly, T.
    Li, C.
    Williams, D. L.
    [J]. SHOCK, 2011, 35 : 41 - 41
  • [43] IGF-1 activates phosphoinositide-3-kinase (PI3K)/Akt/FoxO1 pathway in SZ95 Sebocytes in vitro
    Mirdamadi, Y. S.
    Thielitz, A.
    Wiede, A.
    Papakonstantinou, E.
    Lotzing, M.
    Simeoni, L.
    Zouboulis, C. C.
    Gollnick, H.
    [J]. EXPERIMENTAL DERMATOLOGY, 2013, 22 (03) : E14 - E15
  • [44] OKI-219 is an inhibitor of PI3K α H1047R that has brain penetrance and anti-tumor activity in a preclinical intracranial model of metastatic breast cancer
    Strait, Alexander A.
    Taylor, Molly A.
    Litwiler, Kevin S.
    Zhao, Qian
    Mareska, David A.
    Boys, Mark L.
    Izrayelit, Yevgeniy
    Woessner, Richard
    Winkler, James D.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [45] A study to evaluate the safety and tolerability of the covalent phosphoinositide-3-kinase (PI3K)-alpha Inhibitor, TOS-358, in adult subjects with select solid tumors
    Fakih, Marwan
    Sohal, Davendra P.
    Hafez, Navid
    Berlin, Jordan D.
    Hari, Kimberly
    Trifan, Ovid C.
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [46] The imidazo[1,2-a] pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors
    Stec, Markian M.
    Andrews, Kristin L.
    Bo, Yunxin
    Caenepeel, Sean
    Liao, Hongyu
    McCarter, John
    Mullady, Erin L.
    Miguel, Tisha San
    Subramanian, Raju
    Tamayo, Nuria
    Whittington, Douglas A.
    Wang, Ling
    Wu, Tian
    Zalameda, Leeanne P.
    Zhang, Nancy
    Hughes, Paul E.
    Norman, Mark H.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (19) : 4136 - 4142
  • [47] Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway
    Keeshan, K
    Cotter, TG
    McKenna, SL
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (01) : 34 - 44
  • [48] The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways
    Candido, Saverio
    Salemi, Rossella
    Piccinin, Sara
    Falzone, Luca
    Libra, Massimo
    [J]. PHARMACEUTICS, 2022, 14 (03)
  • [49] The phosphoinositide-3-kinase p101 subunit facilitates membrane translocation of PI3K allowing direct interaction of Gβγ with the catalytic p110γ subunit
    Leopoldt, D
    Maier, U
    Exner, T
    Nürnberg, B
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R657 - R657
  • [50] A Human Immunodeficiency Caused by Mutations in the Phosphoinositide 3-Kinase (PI3K) Regulatory Subunit P85 Alpha Gene PIK3R1 and the Subsequent Hyperactivation of PI3K Signaling
    Deau, M.
    Heurtier, L.
    Frange, P.
    Suarez, F.
    Cavazzana, M.
    Picard, C.
    Durandy, A.
    Fischer, A.
    Kracker, S.
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S164 - S164